Fig. 8: αPD-1 shows synthetic anti-HCC activity in combination with STAT3 inhibitor in vivo.

Orthotopic liver murine models implanted with Hepa1-6-luci⁺ cells were separately treated with PBS combined with DMSO, αPD-1 (10 mg/kg), napabucasin/BBI608 (10 mg/kg), or αPD-1 (10 mg/kg) combined with napabucasin/BBI608 (10 mg/kg) per three days. n = 6 mice. After 18 days, the mice were sacrificed and necropsied. The whole body and organs of mice were weighed after treatment. The dissected tumor tissues were prepared for histological examination, FACS, and immunofluorescence analysis. b Before sacrifice, luciferase marker expression was detected using IVIS. n = 6 mice. c Images of tumor tissue samples were taken from the necropsied orthotopic mice model. n = 6 mice. d, e Histograms showed weight changes in the whole mouse, liver tumor, and liver to mouse ratio in different treatment groups. n = 6 mice. f Multiplexed immunofluorescence images showed the protein expression and location of SAA and Ly6G in each group. g Tumor infiltration of neutrophils (CD11b⁺Ly6G⁺ cells) and PD-L1⁺ neutrophils (PD-L1⁺CD11b⁺Ly6G⁺ cells) were analyzed by FACS in each group. n = 4 mice. h The scheme of the underlying mechanism. The results are expressed as the mean ± SEM. Statistical data presented in this figure show mean ± SEM. ns indicates P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.001, by one-way ANOVA (e, g). Source data and exact P values are provided as a Source Data file. Illustrations created with BioRender.com.